{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:49Z","timestamp":1786985269822,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["413490537"],"award-info":[{"award-number":["413490537"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["01QE2007C"],"award-info":[{"award-number":["01QE2007C"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"publisher","award":["E! 114014"],"award-info":[{"award-number":["E! 114014"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119257","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:28:37Z","timestamp":1774063717000},"page":"119257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer"],"prefix":"10.1016","volume":"198","author":[{"given":"Annika","family":"Brauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Mehdorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-6832","authenticated-orcid":false,"given":"Jan-Paul","family":"Gundlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Putze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5307-3638","authenticated-orcid":false,"given":"Lea","family":"Stahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Heuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-5605","authenticated-orcid":false,"given":"David","family":"Holthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Wesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-8002","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8709-2264","authenticated-orcid":false,"given":"Christer","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Mehli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maxi","family":"Wandmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6582-0083","authenticated-orcid":false,"given":"Susanne","family":"Sebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.biopha.2026.119257_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010820","article-title":"Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models","volume":"13","author":"Ye","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119257_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1160824","article-title":"Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma","volume":"13","author":"Beckinger","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2026.119257_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1157397","article-title":"Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma","volume":"14","author":"Daunke","year":"2023","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119257_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119257_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: new insights and future directions","volume":"229","author":"Espona-Fiedler","year":"2024","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0959-4388(98)80012-3","article-title":"Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations","volume":"8","author":"Br\u00fcmmendorf","year":"1998","journal-title":"Curr. Opin. Neurobiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119257_bib8","first-page":"909","article-title":"Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma","volume":"24","author":"Bergmann","year":"2010","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2026.119257_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jso.21880","article-title":"L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma","volume":"103","author":"Tsutsumi","year":"2011","journal-title":"J. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119257_bib10","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1002\/ijc.33177","article-title":"Recent insights into the role of <scp>L1CAM<\/scp> in cancer initiation and progression","volume":"147","author":"Altevogt","year":"2020","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2011.12.035","article-title":"Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma","volume":"319","author":"Sch\u00e4fer","year":"2012","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/carcin\/bgr262","article-title":"Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent","volume":"33","author":"Sch\u00e4fer","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2026.119257_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149214","article-title":"An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment","volume":"688","author":"Chang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"issue":"16_","key":"10.1016\/j.biopha.2026.119257_bib15","article-title":"A multi-center, open-label phase 1\/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid tumors","volume":"42","author":"Sen","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.biopha.2026.119257_bib16","article-title":"MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: initial dose escalation results in the phase 1 KisMET-01 study","volume":"42","author":"Johnson","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.biopha.2026.119257_bib17","article-title":"First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors","volume":"40","author":"Harvey","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.biopha.2026.119257_bib18","article-title":"A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas","volume":"43","author":"Del Rivero","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119257_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040686","article-title":"Epithelial and mesenchymal-like pancreatic cancer cells exhibit different stem cell phenotypes associated with different metastatic propensities","volume":"16","author":"Philipp","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2026.119257_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.molonc.2014.03.001","article-title":"L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression","volume":"8","author":"Grage-Griebenow","year":"2014","journal-title":"Mol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119257_bib21","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/labinvest.3700329","article-title":"Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine","volume":"85","author":"Jesnowski","year":"2005","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.biopha.2026.119257_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040587","article-title":"Establishment and molecular characterization of two patient-derived pancreatic ductal adenocarcinoma cell lines as preclinical models for treatment response","volume":"12","author":"Braun","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1368603","article-title":"The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma","volume":"7","author":"Lenk","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119257_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ph11020032","article-title":"Antibody-Drug conjugates for cancer therapy: chemistry to clinical implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"13","key":"10.1016\/j.biopha.2026.119257_bib26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/onc.2016.353","article-title":"Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells","volume":"36","author":"Richards","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119257_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119257_bib28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/j.1349-7006.2012.02411.x","article-title":"Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119257_bib29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1208\/s12248-016-9892-3","article-title":"Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design","volume":"18","author":"Maass","year":"2016","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119257_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1535-7163.MCT-23-0437","article-title":"Improving intracellular delivery of an antibody\u2013drug conjugate targeting carcinoembryonic antigen increases efficacy at clinically relevant doses in vivo","volume":"23","author":"Nessler","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119257_bib31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119257_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates","volume":"43","author":"Singh","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"20","key":"10.1016\/j.biopha.2026.119257_bib33","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119257_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7318","article-title":"Comparing in vitro cytotoxic drug sensitivity in colon and pancreatic cancer using 2D and 3D cell models: contrasting viability and growth inhibition in clinically relevant dose and repeated drug cycles","volume":"13","author":"Tidwell","year":"2024","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119257_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102727","article-title":"Promising applications of tumor spheroids and organoids for personalized medicine","volume":"12","author":"Gilazieva","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119257_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100960","article-title":"Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs","volume":"68","author":"Qi","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"8","key":"10.1016\/j.biopha.2026.119257_bib37","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ijc.23703","article-title":"Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma\u2014Epigenetic downregulation of caspases","volume":"123","author":"M\u00fcerk\u00f6ster","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119257_bib38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/0008-5472.CAN-03-1860","article-title":"Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1\u03b2","volume":"64","author":"M\u00fcerk\u00f6ster","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119257_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119257_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2026.119257_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116565","article-title":"Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors","volume":"174","author":"Yuan","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2026.119257_bib42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","article-title":"Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility","volume":"23","author":"K\u00fcnkele","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119257_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00262-025-04142-9","article-title":"Nonclinical safety evaluation and pharmacokinetics of Ab612, a novel anti-L1CAM (CD171) therapeutic antibody candidate against solid cancer","volume":"74","author":"Kim","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2026.119257_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0959-4388(98)80012-3","article-title":"Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations","volume":"8","author":"Br\u00fcmmendorf","year":"1998","journal-title":"Curr. Opin. Neurobiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:44:37Z","timestamp":1779245077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"alternative-id":["S0753332226002908"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119257","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119257"}}